LSP 7 receives 358,680 Evommune shares as award

Evommune, Inc. director and 10% owner LSP 7 Cooperative UA, through its affiliated entity, acquired 358,680 shares of Common Stock as a grant or award on February 17, 2026 at $27.88 per share.

Rhea-AI Filing Summary

Evommune, Inc. director and 10% owner LSP 7 Cooperative UA, through its affiliated entity, acquired 358,680 shares of Common Stock as a grant or award on February 17, 2026 at $27.88 per share. Following this transaction, LSP 7 reported holding 5,288,313 shares indirectly. The shares are held of record by LSP 7 Cooperatief UA, with LSP 7 Management B.V. as sole director; its managing directors may be deemed to share beneficial ownership but each disclaims beneficial ownership of these shares.

Insider Trade Summary

Grant/Award: 358,680 shares

Grant/Award 1 txn

Insider LSP 7 Cooperative UA

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	358,680	$27.88	$10.00M

Holdings After Transaction: Common Stock — 5,288,313 shares (Indirect, See footnote)

Footnotes (1)

1. F1. Securities held of record by LSP 7 Cooperatief UA ("LSP 7"). LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As such, LSP 7 Management B.V., Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to share beneficial ownership of the shares of Common Stock held by LSP 7. Each of Mr. Kleijwegt, Mr. Kuijten and Mr. Rothe disclaims beneficial ownership of such shares.

FAQ

What insider transaction did Evommune (EVMN) report for LSP 7 Cooperative UA?

Evommune reported that LSP 7 Cooperative UA, a director and 10% owner, acquired 358,680 shares of Common Stock as a grant or award at $27.88 per share, increasing its indirect holdings to 5,288,313 shares after the transaction.

How many Evommune (EVMN) shares does LSP 7 hold after this transaction?

After the reported grant or award, LSP 7 Cooperative UA reported indirect ownership of 5,288,313 shares of Evommune Common Stock. This total reflects the newly acquired 358,680 shares added to LSP 7’s prior holdings as of the transaction date.

What was the price and size of the Evommune (EVMN) share grant to LSP 7?

LSP 7 Cooperative UA acquired 358,680 Evommune Common Stock shares at a reported price of $27.88 per share. The transaction is characterized as a grant, award, or other acquisition rather than an open-market purchase.

Is LSP 7’s ownership in Evommune (EVMN) direct or indirect?

LSP 7 Cooperative UA reports its Evommune Common Stock holdings as indirect ownership. The securities are held of record by LSP 7 Cooperatief UA, with LSP 7 Management B.V. serving as sole director over these holdings.

Who may be deemed to share beneficial ownership of Evommune (EVMN) shares held by LSP 7?

LSP 7 Management B.V., as sole director of LSP 7 Cooperatief UA, and its managing directors Martijn Kleijwegt, Rene Kuijten, and Joachim Rothe may be deemed to share beneficial ownership, although each individual disclaims beneficial ownership of the shares.

Was the Evommune (EVMN) transaction by LSP 7 a purchase or an award?

The transaction is classified as a grant, award, or other acquisition of Evommune Common Stock by LSP 7 Cooperative UA, not an open-market purchase or sale, reflecting an award-type issuance of 358,680 shares at a reported price of $27.88 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LSP 7 Cooperative UA

(Last) (First) (Middle)

C/O EQT LIFE SCIENCES,

JOHANNES VERMEERPLEIN 9

(Street)

AMSTERDAM P7 1071 DV

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		A		358,680	A	$27.88	5,288,313	I	See footnote(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Securities held of record by LSP 7 Cooperatief UA ("LSP 7"). LSP 7 Management B.V. is the sole director of LSP 7. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As such, LSP 7 Management B.V., Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be deemed to share beneficial ownership of the shares of Common Stock held by LSP 7. Each of Mr. Kleijwegt, Mr. Kuijten and Mr. Rothe disclaims beneficial ownership of such shares.

	LSP 7 Cooperatief UA, By: LSP 7 Management B.V., its sole director, /s/ Martijn Kleijwegt, Managing Director and /s/ Rene Kuijten, Managing Director	02/19/2026
	LSP 7 Management B.V., By: /s/ Martijn Kleijwegt, Managing Director and /s/ Rene Kuijten, Managing Director	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.